HK Innoen Receives Product Approval for K-CAB Tablets in the Philippines
[Asia Economy Reporter Junho Hwang] HK inno.N announced on the 23rd that it has received product approval for K-CAB tablets in the Philippines from the Philippine Food and Drug Administration.
The company stated, "With the acquisition of local product approval for K-CAB tablets (tegoprazan), a treatment for gastroesophageal reflux disease, starting from the Philippines, we will actively enter the Southeast Asian market and contribute to the expansion of overseas sales."
Hot Picks Today
SpaceX Opens IPO Floodgates... Anthropic and OpenAI Push Valuations into the Trillions
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "Insisting on Phone Consultations Only for Hearing-Impaired Clients"... Human Rights Commission Recommends Staff Training for Foundation
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
It added, "K-CAB tablets (tegoprazan) are drugs with a P-CAB (Potassium-competitive acid blocker) mechanism that reversibly block proton pumps responsible for secreting gastric acid in the stomach lining, thereby suppressing acid secretion," and "they show faster and more sustained effects compared to drugs with a PPI (Proton Pump Inhibitor) mechanism."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
